Article and Video CATEGORIES

Cancer Journey

Search By

Induction Chemotherapy Followed by Chemo/Radiation for Stage III NSCLC
Thu, 02/11/2016 - 06:00
GRACE Videos and Articles
GRACE Cancer Video Library - Lung



Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.



One of the areas of controversy is with regard to induction chemotherapy, followed by chemoradiotherapy in stage III disease. I mentioned before that systemic micrometastatic disease is a huge problem in these patients, and one has to give adequate, effective chemotherapy in this setting. We typically give chemotherapy with radiation, but radiotherapy strategies typically last six to seven weeks, and therefore, that would really account for essentially two cycles of chemotherapy. Now, in stage II or III when we are giving adjuvant therapy, or in the metastatic stage IV setting, our current standard is to give four cycles of chemotherapy in that setting, maybe sometimes six in the stage IV setting, so I’ve always wondered why would we just give two cycles concurrent with chemoradiotherapy in the stage III setting?

However, I will tell you that all the level one evidence does not routinely support the use of more chemotherapy, other than during the radiotherapy. Obviously, it could be given before, as so-called induction, or it could be given after chemoradiation, so-called consolidation therapy. Many investigators have pursued giving two cycles prior to initiation of chemoradiation — that’s a strategy that I like personally, and frequently do in my practice. I don’t have level one evidence to suggest that it’s a strategy that has, in clinical trials, which in my opinion have been limited and relatively small in number, so relatively underpowered in this setting — but the advantage of induction therapy is, often patients are symptomatic, the response rates tend to be in the 40-60%, depending upon which study you look at — a response makes the patient feel better because their symptoms may get better, but the other thing it does is that it may allow a smaller field of radiation, if you believe that it’s okay to treat the volume of cancer that is present after chemotherapy, which is what we do at our particular center. So it may allow a smaller field of radiation be using induction therapy, that may then reduce the toxicities you may see during chemoradiation.

Again, this strategy has not been proven at the phase III level one evidence. However, it’s very commonly used and I will also note that it’s very common for a practicing oncologist to recommend two cycles of consolidation chemotherapy if the initial treatment is concurrent chemoradiotherapy. So rather than give chemotherapy before, it’s given afterwards. Again, not a proven strategy at the phase III level one evidence point of view, however, many of our major clinical trials done in cooperative groups allow two cycles as consolidation therapy, which is typically what is commonly done in practice.

My personal bias is that you should think about giving four cycles in this particular setting. I think two cycles are inadequate to control micrometastatic disease, particularly if during radiation, the chemotherapy strategy that is pursued is low-dose weekly approaches, which may not be the optimal way to control systemic disease.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Mandarin LCVL
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit:…;  
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Blood Cancer OncTalk
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29